WHO ICTRP trial
Intravenous Dexmedetomidine versus Nebulised Dexmedetomidine for procedural…
IRCT20221109056455N2 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20221109056455N2 |
|---|---|
| Public title | Intravenous Dexmedetomidine versus Nebulised Dexmedetomidine for procedural sedation during ERCP |
| Scientific title | Intravenous Dexmedetomidine versus Nebulised Dexmedetomidine in combination with standardised Propofol-Fentanyl-Midazolam for Procedural sedation during ERCP: a comparative evaluation of sedation efficacy |
| Primary sponsor | Tata Main Hospital, Jamshedpur |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | India |
| Conditions | choledocholithiasis with obstruction. Other cholelithiasis with obstruction;K80.81 |
| Interventions | Intervention 1: Intervention group: Group NEB-DEX will receive nebulized dexmedetomidine 1 µg/kg diluted in normal saline (0.9%) to a volume of 5 ml 30 minutes prior to induction of anesthesia. Intervention 2: Control group: Group IVDEX… |
| Registration date | Sep 26, 2024 |
| Target size | 70 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: